Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.

  title={Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.},
  author={Phillip Lee Palmbos and Maha H A Hussain},
  volume={30 5},
Metastatic prostate cancer remains a highly lethal disease with no curative therapeutic options. A significant subset of patients with prostate cancer harbor either germline or somatic mutations in DNA repair enzyme genes such as BRCA1, BRCA2, or ATM. Emerging data suggest that drugs that target poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) enzymes may represent a novel and effective means of treating tumors with these DNA repair defects, including prostate cancers. Here we will… CONTINUE READING
This paper has been referenced on Twitter 1 time. VIEW TWEETS